Current through Register Vol. 63, No. 9, September 1, 2024
(1) "Collaborative Drug Therapy Management"
as used in this section means the participation by a physician and a pharmacist
in the management of drug therapy pursuant to a written protocol that includes
information specific to the dosage, frequency, duration and route of
administration of the drug, authorized by a physician and initiated upon a
prescription order for an individual patient and:
(a) Is agreed to by one physician and one
pharmacist; or
(b) Is agreed to by
one or more physicians in a single organized medical group, such as a hospital
medical staff, clinic or group practice, including but not limited to organized
medical groups using a pharmacy and therapeutics committee, and one or more
pharmacists.
(2) A
physician shall engage in collaborative drug therapy management with a
pharmacist only under a written arrangement that includes:
(a) The identification, either by name or by
description, of the participating pharmacist(s);
(b) The identification, by name, of the
participating physician(s);
(c) The
name of the physician and principal pharmacist who are responsible for
development, training, administration, and quality assurance of the
arrangement;
(d) A detailed
description of the collaborative role the pharmacist(s) shall play, including
but not limited to:
(A) Written protocol for
specific drugs pursuant to which the pharmacist will base drug therapy
management decisions for an individual patient;
(B) Circumstances which will cause the
pharmacist to initiate communication with the physician, including but not
limited to the need for new prescription orders and reports of patients'
therapeutic responses or adverse effects;
(C) Training requirement for pharmacist
participation and ongoing assessment of competency, if necessary;
(D) Quality assurance and periodic review by
a panel of the participating physicians(s) and pharmacist(s).
(e) Authorization by the
physician(s) for the pharmacist(s) to participate in the collaborative drug
therapy;
(f) A provision for the
collaborative drug therapy arrangement to be reviewed and updated, or
discontinued at least every two years; and
(g) A description of the mechanism for the
pharmacist(s) to communicate to the physician(s) and for documentation of the
implementation of the collaborative drug therapy.
(3) Nothing in this rule shall be construed
to allow therapeutic substitution.
(4) The collaborative drug therapy protocol
must be kept on file in the pharmacy and made available to the Board of
Pharmacy and the Oregon Medical Board upon request.
